Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CeriBell, Inc. (Nasdaq: CBLL) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a medical technology company focused on point-of-care electroencephalography (EEG) for serious neurological conditions, CeriBell uses its filings to report financial performance, material agreements, intellectual property actions, and key product milestones related to the Ceribell System.
Investors can review periodic reports and current reports on Form 8-K that describe quarterly financial results, including separate disclosure of product revenue and subscription revenue, as well as updates on cash, marketable securities, and operating expenses. Filings also cover material definitive agreements, such as the Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University for patent rights related to portable brain wave devices, and the Corporate Supply Agreement with Shenzhen Everwin Precision Technology Co., Ltd. and affiliates for EEG headband supply and related licenses.
Other 8-K filings document regulatory and legal developments, including announcements of FDA 510(k) clearance for the Clarity® algorithm in neonatal seizure detection, clearance for the company’s delirium monitoring solution, and the FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor. Filings also describe patent infringement complaints filed against Natus Medical Incorporated and related subsidiaries, as well as lease amendments for office space in Sunnyvale, California and governance changes such as the election of new directors.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand financial trends, material contracts, regulatory events, and intellectual property issues affecting CBLL. Users can also track insider-related disclosures when available through forms such as Form 4, and refer to annual reports on Form 10-K and quarterly reports on Form 10-Q for deeper insight into CeriBell’s business, risk factors, and operations.
Ceribell, Inc. Chief Financial Officer Scott Blumberg reported an open-market sale of 808 shares of common stock on February 23, 2026 at a price of $19.79 per share. The sale was made to cover tax withholding obligations related to vesting restricted stock units. Following this transaction, he directly holds 118,334 shares, which includes 300 shares acquired under Ceribell's Employee Stock Purchase Plan on January 30, 2026.
Ceribell, Inc. President and CEO Chao Xingjuan reported an open-market sale of 2,084 shares of common stock on February 23, 2026 at $19.79 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units.
After this transaction, she directly owned 725,164 common shares. The filing also notes an indirect holding of 369,088 shares through the ACP 2021 Trust, where she is a co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership beyond her pecuniary interest.
CeriBell, Inc. is a medical technology company focused on point-of-care EEG for critically ill patients, using AI-powered algorithms to detect seizures, delirium and other serious neurological conditions. Its Ceribell System combines disposable headbands or headcaps, a pocket-sized recorder and a cloud portal for real-time monitoring.
As of December 31, 2025, the system had been adopted by more than 600 U.S. hospitals, targeting a U.S. addressable market it estimates at over $3.5 billion when including seizures and delirium. In 2025 CeriBell generated $89.1 million in revenue, up from $65.4 million in 2024, with a gross margin of 88% and a net loss of $53.4 million.
Growth is supported by expanding clinical indications: FDA 510(k) clearance for its Clarity algorithm to diagnose electrographic status epilepticus in adults and for delirium monitoring, plus Breakthrough Device Designation for an in‑development large vessel occlusion stroke detection solution. The company relies on recurring revenue from single-use Wearables and subscriptions to its software and hardware platform.
Ceribell, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining loss-making. Fourth quarter revenue rose 34% to $24.8 million, with product revenue up 33% and subscription revenue up 37%. Gross margin was a high 87%, but operating expenses increased 24% to $36.2 million, leading to a net loss of $13.5 million, or $0.36 per share.
For full year 2025, revenue grew 36% to $89.1 million, driven by both product and subscription sales. Gross profit reached $78.3 million with an improved gross margin of 88%, but operating expenses rose 42% to $136.7 million, resulting in a net loss of $53.4 million, or $1.46 per share. Ceribell ended the year with $159.3 million in cash, cash equivalents, and marketable securities and 647 active accounts.
The company highlighted multiple regulatory milestones, including two FDA 510(k) clearances and an FDA Breakthrough Device Designation, and guided 2026 revenue to $111–115 million, implying about 25–29% growth over 2025.
CBLL: A Form 144 excerpt lists multiple reported sales of common stock by David J. Foehr. The excerpt shows sales on 12/03/2025 of 5,265 shares for $88,609.95; on 01/05/2026 of 5,556 shares for $125,565.60; on 02/03/2026 of 5,556 shares for $111,120.00; and on 02/23/2026 of 569 shares for $11,263.07. The excerpt also notes restricted stock vesting on 02/20/2026 for 781 shares identified as compensation.
Insider Form 144 reports multiple dispositions of common stock. The filing lists planned sale/transfer of 705 common shares associated with a 02/20/2026 restricted stock vesting through Fidelity Brokerage Services LLC. It also discloses three recent open-market dispositions by Raymond Woo of 11,112 shares each on 12/01/2025, 01/02/2026, and 02/02/2026 with aggregate proceeds shown per sale.
Xingjuan Chao reported intent to sell 2,084 common shares associated with restricted stock vesting on 02/20/2026. The filing also discloses prior dispositions of 79,000 shares on 01/05/2026 and 39,000 shares on 02/04/2026, with cash amounts shown for each trade.
Scott E. Blumberg reported a sale of common stock. He indicated an intent to sell 808 shares of Common Stock on 02/20/2026 tied to restricted stock vesting as issuer compensation. The filing also records a prior sale of 36,000 shares on 12/22/2025 for $756,000.
David J. Foehr reported sales of Common stock and a proposed resale notice under Rule 144. The filing lists three recent sales: 5,265 shares on 12/03/2025, 5,556 shares on 01/05/2026, and 5,556 shares on 02/03/2026. It also shows a restricted stock vesting event dated 02/20/2026 involving 569 shares and identifies Fidelity Brokerage Services LLC as the broker.